keyword
MENU ▼
Read by QxMD icon Read
search

Exenatide without diabetes

keyword
https://read.qxmd.com/read/30720240/redox-active-injectable-gel-using-polyion-complex-to-achieve-sustained-release-of-exenatide-and-enhance-therapeutic-efficacy-for-the-treatment-of-type-2-diabetes
#1
Shiro Ishii, Shou Sakaue, Yukio Nagasaki
To provide sustained release of exenatide and enhance therapeutic efficacy for the treatment of type 2 diabetes compared to the existing products for exenatide, we developed an exenatide-loaded, redox-active, injectable gel (Exe@RIG). This injectable gel is formed by a polyion complex (PIC) comprising three components, (1) cationic polyamine-poly(ethylene glycol)-polyamine triblock copolymer possessing reactive oxygen species (ROS)-scavenging moieties as side chains, (2) anionic poly(acrylic acid), and (3) exenatide...
February 5, 2019: Journal of Biomedical Materials Research. Part A
https://read.qxmd.com/read/30690693/exenatide-delays-gastric-emptying-in-patients-with-type-2-diabetes-mellitus-but-not-in-those-with-gastroparetic-conditions
#2
Christelle Beti, Bernd Stratmann, Georgy Bokman, Jens Dreier, Michael Hauber, Young Hee Lee-Barkey, Manfred Fischer, Cornelius Knabbe, Diethelm Tschoepe
The effect of the treatment with glucagon-like peptide (GLP)-1 receptor agonists on gastric emptying in patients with diabetes with and without gastroparesis is analysed. Patients with type 2 diabetes mellitus subjected to GLP-1 receptor agonist therapy with exenatide were examined before and shortly after initiation of treatment. Gastric half-emptying time was determined by 13 C-octanoic breath test; routine laboratory parameter as well as active GLP-1, ghrelin, leptin, insulin, proinsulin and C-peptide levels were determined in fasting state as well as postprandial secretion within 1 h after a standardised meal...
January 28, 2019: Hormone and Metabolic Research, Hormon- und Stoffwechselforschung, Hormones et Métabolisme
https://read.qxmd.com/read/30635783/combination-of-insulin-with-a-glp1-agonist-is-associated-with-better-memory-and-normal-expression-of-insulin-receptor-pathway-genes-in-a-mouse-model-of-alzheimer-s-disease
#3
Ari Robinson, Irit Lubitz, Dana Atrakchi-Baranes, Avital Licht-Murava, Pavel Katsel, Derek Leroith, Sigal Liraz-Zaltsman, Vahram Haroutunian, Michal Schnaider Beeri
Disruption of brain insulin signaling may explain the higher Alzheimer's disease (AD) risk among type 2 diabetic (T2D) patients. There is evidence from in vitro and human postmortem studies that combination of insulin with hypoglycemic medications is neuroprotective and associated with less amyloid aggregation. We examined the effect of 8-month intranasal administration of insulin, exenatide (a GLP-1 agonist), combination therapy (insulin + exenatide) or saline, in wild-type (WT) and an AD-like mouse model (Tg2576)...
January 11, 2019: Journal of Molecular Neuroscience: MN
https://read.qxmd.com/read/30538516/is-there-an-association-between-liraglutide-use-and-female-breast-cancer-in-a-real-world-setting
#4
Donnie Funch, Kathleen Mortimer, Ling Li, Heather Norman, Atheline Major-Pedersen, Anne Helene Olsen, Margit S Kaltoft, David D Dore
Background: Liraglutide is a human glucagon-like peptide-1 receptor agonist approved for treatment of adults with type 2 diabetes mellitus at a maximum dose of 1.8 mg/day (Victoza® ) and more recently at 3.0 mg/day for weight management (Saxenda® ). During the evaluation of liraglutide for approval in weight management, a minor imbalance in the numbers of reported breast neoplasms was observed, motivating the present study. Our objective was to quantify the association between liraglutide and incidence of breast cancer (BC) among women in a real-world setting...
2018: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
https://read.qxmd.com/read/30516068/managing-diabetes-and-preventing-heart-disease-have-we-found-a-safe-and-effective-agent
#5
Judy W M Cheng, Vincent J Colucci, James S Kalus, Sarah A Spinler
OBJECTIVE: While improving glycemic control with antihyperglycemics has been demonstrated to reduce microvascular complications, the benefits of reduction in cardiovascular diseases (CVDs) have not been demonstrated with older agents. This article reviews current evidence of the CV outcomes of newer antihyperglycemics approved since 2008. DATA SOURCES: Peer-reviewed articles were identified from MEDLINE (1966 to October 31, 2018) using search terms exenatide, liraglutide, lixisenatide, dulaglutide, semaglutide, alogliptin, linagliptin, saxagliptin, sitagliptin, canagliflozin, dapagliflozin, empagliflozin, mortality, myocardial infarction (MI), heart failure (HF), and stroke...
December 5, 2018: Annals of Pharmacotherapy
https://read.qxmd.com/read/30372907/recent-updates-on-glp-1-agonists-current-advancements-challenges
#6
REVIEW
Dilip Sharma, Suril Verma, Shivani Vaidya, Kiran Kalia, Vinod Tiwari
Glucagon-like peptide (GLP)-1 is an incretin hormone exhibiting several pharmacological actions such as neuroprotection, increased cognitive function, cardio-protection, decreased hypertension, suppression of acid secretion, increase in lyposis, and protection from inflammation. The most potent actions are glucose-dependent insulinotropic and glucagonostatic actions, stimulation of β-cell proliferation, enhanced insulin secretion and reduced weight gain in patients with type-2 diabetes pertaining to blood glucose control...
December 2018: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://read.qxmd.com/read/30371301/effect-of-once-weekly-exenatide-on-clinical-outcomes-according-to-baseline-risk-in-patients-with-type-2-diabetes-mellitus-insights-from-the-exscel-trial
#7
Robert J Mentz, M Angelyn Bethel, Peter Merrill, Yuliya Lokhnygina, John B Buse, Juliana C Chan, João S Felício, Shaun G Goodman, Jasmine Choi, Stephanie M Gustavson, Nayyar Iqbal, Renato D Lopes, Aldo P Maggioni, Peter Öhman, Neha J Pagidipati, Neil R Poulter, Ambady Ramachandran, Barry Reicher, Rury R Holman, Adrian F Hernandez
Background In the EXSCEL (Exenatide Study of Cardiovascular Event Lowering), exenatide once-weekly resulted in a nonsignificant reduction in major adverse cardiovascular events ( MACEs ) and a nominal 14% reduction in all-cause mortality in 14 752 patients with type 2 diabetes mellitus (T2 DM ) with and without cardiovascular disease. Whether patients at increased risk for events experienced a comparatively greater treatment benefit with exenatide is unknown. Methods and Results In the EXSCEL population, we created risk scores for MACEs and all-cause mortality using step-wise selection of baseline characteristics...
October 2, 2018: Journal of the American Heart Association
https://read.qxmd.com/read/29950475/protocol-for-meal-time-administration-of-exenatide-for-glycaemic-control-in-type-1-diabetes-cases-the-mag1c-trial-a-randomised-double-blinded-placebo-controlled-trial
#8
Nicklas Järvelä Johansen, Thomas Fremming Dejgaard, Asger Lund, Tina Vilsbøll, Henrik Ullits Andersen, Filip Krag Knop
INTRODUCTION: Persons with type 1 diabetes require intensive insulin therapy to achieve glycaemic control, but side effects, including hypoglycaemia and weight gain, may reduce treatment compliance. We hypothesise that add-on treatment of the short-acting glucagon-like peptide-1 receptor agonist, exenatide, to insulin therapy in persons with type 1 diabetes will reduce insulin requirements, glycaemic excursions and body weight and improve glycaemic control without increasing the risk of hypoglycaemia...
June 27, 2018: BMJ Open
https://read.qxmd.com/read/29949016/a-randomized-controlled-trial-of-dapagliflozin-plus-once-weekly-exenatide-versus-placebo-in-individuals-with-obesity-and-without-diabetes-metabolic-effects-and-markers-associated-with-bodyweight-loss
#9
Maria J Pereira, Per Lundkvist, Prasad G Kamble, Joey Lau, Julian G Martins, C David Sjöström, Volker Schnecke, Anna Walentinsson, Eva Johnsson, Jan W Eriksson
INTRODUCTION: The sodium-glucose cotransporter 2 inhibitor dapagliflozin and the glucagon-like peptide-1 (GLP-1) receptor agonist exenatide reduce bodyweight via differing and complementary mechanisms. This post hoc analysis investigated the metabolic effects and baseline associations with bodyweight loss on coadministration of dapagliflozin and exenatide once weekly (QW) among adults with obesity and without diabetes. METHODS: In the primary trial, adults with obesity and without diabetes [n = 50; 18-70 years; body mass index (BMI) 30-45 kg/m2 ] were randomized to double-blind oral dapagliflozin 10 mg (DAPA) once daily plus subcutaneous long-acting exenatide 2 mg QW (ExQW) or placebo over 24 weeks, followed by an open-label extension from 24-52 weeks during which all participants received active treatment...
August 2018: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://read.qxmd.com/read/29862621/achieving-glycaemic-control-without-weight-gain-hypoglycaemia-or-gastrointestinal-adverse-events-in-type-2-diabetes-in-the-sustain-clinical-trial-programme
#10
J Hans DeVries, Cyrus Desouza, Srikanth Bellary, Jeffrey Unger, Oluf K H Hansen, Jeppe Zacho, Vincent Woo
AIM: To evaluate the potential for semaglutide to help people with type 2 diabetes (T2D) achieve glycated haemoglobin (HbA1c) targets while avoiding unwanted outcomes, such as weight gain, hypoglycaemia and gastrointestinal (GI) side effects. MATERIALS AND METHODS: Data from the phase IIIa SUSTAIN 1 to 5 clinical trials were analysed. Participants had inadequately controlled T2D and were drug-naïve (SUSTAIN 1) or on a range of background treatments (SUSTAIN 2 to 5)...
October 2018: Diabetes, Obesity & Metabolism
https://read.qxmd.com/read/29541641/exenatide-with-metformin-ameliorated-visceral-adiposity-and-insulin-resistance
#11
Xuan Du, Wen Lu, Zijun Lu, Xinyu Shao, Chunhong Hu, Bimin Shi
Background: To study the effectiveness of exenatide with metformin and sequential treatment with exenatide and glargine added to metformin and their influence on insulin sensitivity and adipose distribution. Methods: 20 newly diagnosed obese type 2 diabetic patients were enrolled, and 2-month washout treatment of metformin, 6-month exenatide treatment, and 6-month glargine treatment were administrated sequentially accompanied with previous metformin. Glucolipid metabolic parameters were compared among groups...
2018: Journal of Diabetes Research
https://read.qxmd.com/read/29473704/effect-of-exenatide-qw-or-placebo-both-added-to-titrated-insulin-glargine-in-uncontrolled-type-2-diabetes-the-duration-7-randomized-study
#12
Cristian Guja, Juan P Frías, Aniko Somogyi, Serge Jabbour, Hui Wang, Elise Hardy, Julio Rosenstock
AIMS: To compare the efficacy and safety of adding the glucagon-like peptide-1 receptor agonist exenatide once weekly (QW) 2 mg or placebo among patients with type 2 diabetes who were inadequately controlled despite titrated insulin glargine (IG) ± metformin. METHODS: This multicentre, double-blind study (ClinicalTrials.gov identifier: NCT02229383) randomized (1:1) patients with persistent hyperglycaemia after an 8-week titration phase (glycated haemoglobin [HbA1c] 7...
July 2018: Diabetes, Obesity & Metabolism
https://read.qxmd.com/read/29221659/cardiovascular-outcomes-with-glucagon-like-peptide-1-receptor-agonists-in-patients-with-type-2-diabetes-a-meta-analysis
#13
M Angelyn Bethel, Rishi A Patel, Peter Merrill, Yuliya Lokhnygina, John B Buse, Robert J Mentz, Neha J Pagidipati, Juliana C Chan, Stephanie M Gustavson, Nayyar Iqbal, Aldo P Maggioni, Peter Öhman, Neil R Poulter, Ambady Ramachandran, Bernard Zinman, Adrian F Hernandez, Rury R Holman
BACKGROUND: Glucagon-like peptide-1 (GLP-1) receptor agonists are effective glucose-lowering drugs. Findings from cardiovascular outcome trials showed cardiovascular safety of GLP-1 receptor agonists, but results for cardiovascular efficacy were varied. We aimed to examine overall cardiovascular efficacy for lixisenatide, liraglutide, semaglutide, and extended-release exenatide. METHODS: In this systematic review and meta-analysis, we analysed data from eligible trials that assessed the safety and efficacy of GLP-1 receptor agonists compared with placebo in adult patients (aged 18 years or older) with type 2 diabetes and had a primary outcome including, but not limited to, cardiovascular mortality, non-fatal myocardial infarction, and non-fatal stroke...
February 2018: Lancet Diabetes & Endocrinology
https://read.qxmd.com/read/29217653/exenatide-treatment-causes-suppression-of-serum-fasting-ghrelin-levels-in-patients-with-type-2-diabetes-mellitus
#14
Metin Guclu, Sinem Kiyici, Zulfiye Gul, Sinan Cavun
AIM: In the present study, we investigated the long-term effects of exenatide treatment on serum fasting ghrelin levels in patients with type 2 diabetes mellitus. METHODS: Type 2 diabetic patients, who were using metformin with and without the other antihyperglycemic drugs on a stable dose for at least 3 months, were enrolled in the study. BMI>35 kg/m2 and HbA1c>7.0% were the additional inclusion criteria. Oral antihyperglycemic drugs, other than metformin, were stopped, and metformin treatment was continued at 2000 mg per day...
January 2018: Endocrine Connections
https://read.qxmd.com/read/29194917/treatment-of-clozapine-associated-obesity-and-diabetes-with-exenatide-in-adults-with-schizophrenia-a-randomized-controlled-trial-codex
#15
Dan J Siskind, Anthony W Russell, Clare Gamble, Karl Winckel, Karla Mayfield, Sam Hollingworth, Ingrid Hickman, Victor Siskind, Steve Kisely
Clozapine causes obesity and type 2 diabetes (T2DM). Glucagon-like peptide-1 (GLP-1) receptor agonists (e.g. exenatide) can counter clozapine-associated GLP-1 dysregulation in animals, and may be beneficial in people on clozapine. This randomized, controlled, open-label, pilot trial evaluated weekly exenatide for weight loss among clozapine-treated obese adults with schizophrenia, with or without T2DM. A total of 28 outpatients were randomized to once-weekly extended-release subcutaneous exenatide or usual care for 24 weeks...
April 2018: Diabetes, Obesity & Metabolism
https://read.qxmd.com/read/29044860/effects-of-exenatide-twice-daily-exenatide-once-weekly-or-insulin-in-patients-with-type-2-diabetes-and-baseline-hba1c-%C3%A2-10-0-two-pooled-analyses-including-20-randomised-controlled-trials
#16
REVIEW
Robert S Busch, James Ruggles, Jenny Han, Elise Hardy
AIMS: Patients with advanced type 2 diabetes (T2D) and high glycated haemoglobin (HbA1c) values can be difficult to treat because of their severe metabolic disease. This pooled analysis examined the treatment effects of exenatide twice daily (BID), exenatide once weekly (QW) and insulin in patients with high baseline HbA1c (≥10.0%). METHODS: This post hoc analysis used pooled data from 12 and 8 randomised controlled trials of exenatide BID and exenatide QW, respectively...
December 2017: International Journal of Clinical Practice
https://read.qxmd.com/read/28932995/pharmacokinetics-and-preliminary-pharmacodynamics-of-single-and-multiple-dose-lyophilized-recombinant-glucagon-like-peptide-1-receptor-agonist-re-4-in-chinese-patients-with-type-2-diabetes-mellitus
#17
RANDOMIZED CONTROLLED TRIAL
Yitong Wang, Bingfeng Xu, Lixia Zhu, Kun Lou, Yingli Chen, Xia Zhao, Qian Wang, Ling Xu, Xiaohui Guo, Linong Ji, Yimin Cui, Yi Fang
BACKGROUND AND OBJECTIVES: Recombinant glucagon-like peptide-1 receptor agonist (rE-4) is a glucagon-like peptide-1 receptor agonist, which has the same amino acid sequence to exenatide, except for the C-terminal deamidated. This study assessed the pharmacokinetics and preliminary pharmacodynamics of rE-4, following single and multiple subcutaneous injections in Chinese patients with type 2 diabetes mellitus (T2DM). DESIGN AND METHODS: In the randomized, open-label study, Chinese patients with T2DM (n = 36) were randomly assigned to three groups of rE-4 (n = 12), rE-4 with metformin (n = 12) and exenatide (n = 12, as the control group) for 12 weeks...
December 2017: Clinical Drug Investigation
https://read.qxmd.com/read/28910237/effects-of-once-weekly-exenatide-on-cardiovascular-outcomes-in-type-2-diabetes
#18
RANDOMIZED CONTROLLED TRIAL
Rury R Holman, M Angelyn Bethel, Robert J Mentz, Vivian P Thompson, Yuliya Lokhnygina, John B Buse, Juliana C Chan, Jasmine Choi, Stephanie M Gustavson, Nayyar Iqbal, Aldo P Maggioni, Steven P Marso, Peter Öhman, Neha J Pagidipati, Neil Poulter, Ambady Ramachandran, Bernard Zinman, Adrian F Hernandez
BACKGROUND: The cardiovascular effects of adding once-weekly treatment with exenatide to usual care in patients with type 2 diabetes are unknown. METHODS: We randomly assigned patients with type 2 diabetes, with or without previous cardiovascular disease, to receive subcutaneous injections of extended-release exenatide at a dose of 2 mg or matching placebo once weekly. The primary composite outcome was the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke...
September 28, 2017: New England Journal of Medicine
https://read.qxmd.com/read/28794822/overview-of-glucagon-like-peptide-1-receptor-agonists-for-the-treatment-of-patients-with-type-2-diabetes
#19
Kelvin Lingjet Tran, Young In Park, Shalin Pandya, Navin John Muliyil, Brandon David Jensen, Kovin Huynh, Quang T Nguyen
BACKGROUND: It is estimated that 29.1 million people or 9.3% of the US population have diabetes, which contributes to considerable medical and financial burden. Type 2 diabetes mellitus is characterized by insulin resistance and insulin secretion impairment leading to hyperglycemia. The presence of insulin resistance is strongly correlated with obesity. OBJECTIVE: This article reviews the available glucagon-like peptide-1 (GLP-1) receptor agonists and their role in the management of patients with diabetes, to help guide the selection of the most suitable agent for the individualized treatment of patients with type 2 diabetes...
June 2017: American Health & Drug Benefits
https://read.qxmd.com/read/28454792/baseline-characteristics-of-patients-enrolled-in-the-exenatide-study-of-cardiovascular-event-lowering-exscel
#20
RANDOMIZED CONTROLLED TRIAL
Robert J Mentz, M Angelyn Bethel, Stephanie Gustavson, Vivian P Thompson, Neha J Pagidipati, John B Buse, Juliana C Chan, Nayyar Iqbal, Aldo P Maggioni, Steve P Marso, Peter Ohman, Neil Poulter, Ambady Ramachandran, Bernard Zinman, Adrian F Hernandez, Rury R Holman
BACKGROUND: EXSCEL is a randomized, double-blind, placebo-controlled trial examining the effect of exenatide once-weekly (EQW) versus placebo on time to the primary composite outcome (cardiovascular death, nonfatal myocardial infarction or nonfatal stroke) in patients with type 2 diabetes mellitus (DM) and a wide range of cardiovascular (CV) risk. METHODS: Patients were enrolled at 688 sites in 35 countries. We describe their baseline characteristics according to prior CV event status and compare patients with those enrolled in prior glucagon-like peptide-1 receptor agonist (GLP-1RA) outcomes trials...
May 2017: American Heart Journal
keyword
keyword
110086
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"